Join
Live feed
·
PRReleasevia Quantisnow
Alpha Tau Medical Ltd. logo

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

ByQuantisnow·Wall Street's wire, on your screen.
DRTS· Alpha Tau Medical Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DRTS (Alpha Tau Medical Ltd.) and more on Quantisnow.